Inovio Pharmaceuticals (NASDAQ:INO) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Inovio Pharmaceuticals (NASDAQ:INO) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Positive Sentiment: INO-3107’s FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed.
• Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity.
• Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results.
• Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July’s $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises.
• Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock traded up $0.00 during midday trading on Wednesday, reaching $0.77. The stock had a trading volume of 3,060,340 shares, compared to its average volume of 2,293,542. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.98. The stock has a market capitalization of $63.35 million, a PE ratio of -0.53 and a beta of 1.52. The stock’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $1.31.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its holdings in shares of Inovio Pharmaceuticals by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after purchasing an additional 42,146 shares during the period. Vanguard Group Inc. increased its position in Inovio Pharmaceuticals by 35.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock worth $6,348,000 after purchasing an additional 703,727 shares in the last quarter. Millennium Management LLC raised its holdings in Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock valued at $4,616,000 after buying an additional 1,625,653 shares during the period. Geode Capital Management LLC raised its holdings in Inovio Pharmaceuticals by 40.7% in the fourth quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company’s stock valued at $1,340,000 after buying an additional 222,609 shares during the period. Finally, UBS Group AG lifted its position in Inovio Pharmaceuticals by 46.8% during the third quarter. UBS Group AG now owns 293,062 shares of the biopharmaceutical company’s stock valued at $686,000 after buying an additional 93,383 shares in the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. HC Wainwright lowered their price target on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a report on Monday, June 1st. Wall Street Zen lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, June 21st. Weiss Ratings raised shares of Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Inovio Pharmaceuticals has an average rating of “Hold” and an average target price of $3.25.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.